Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Adjusted Vorinostat in Primary Cutaneous T-Cell Lymphoma
NCT00958074Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Jul 2009
- Primary completion
- Feb 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in cutaneous T-cell lymphoma (CTCL), sponsored by University of Washington. Started Jul 2009; status: terminated.
02
Drugs
vorinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00958074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958074.